Aug 2025· International Journal of Epidemiology· Vol 55· 1 citation· 39 references
BiologyComputer ScienceMathematicsMedicine
TL;DR
Adversarial random forests (ARF) reliably generates high-quality synthetic data that replicate diverse epidemiological analyses while offering a competitive privacy–utility trade-off.
Abstract
Abstract Background Synthetic data hold substantial potential to address practical challenges in epidemiology due to restricted data access and privacy concerns. However, many current methods suffer from limited quality, high computational demands, and complexity for non-experts. Furthermore, common evaluation strategies for synthetic data often fail to directly reflect statistical utility and measure privacy risks sufficiently. Against this background, a critical underexplored question is whether synthetic data can reliably reproduce key findings from epidemiological research while preserving privacy. Methods We propose adversarial random forests (ARF) as an efficient and convenient method for synthesizing tabular epidemiological data. To evaluate its performance, we replicated statistical analyses from six epidemiological publications covering blood pressure, anthropometry, myocardial infarction, accelerometry, loneliness, and diabetes, from the German National Cohort (NAKO Gesundheitsstudie), the Bremen STEMI Registry U45 Study, and the Guelph Family Health Study. We further assessed how dataset dimensionality and variable complexity affect the quality of synthetic data, and contextualized ARF’s performance by comparison with commonly used tabular data synthesizers in terms of utility, privacy, generalization, and runtime. Results Across all replicated studies, results on ARF-generated synthetic data consistently aligned with original findings. Even for datasets with relatively low sample size-to-dimensionality ratios, replication outcomes closely matched the original results across descriptive and inferential analyses. Reduced dimensionality and variable complexity further enhanced synthesis quality. ARF demonstrated favourable performance regarding utility, privacy preservation, and generalization relative to other synthesizers and superior computational efficiency. Conclusions In summary, ARF reliably generates high-quality synthetic data that replicate diverse epidemiological analyses while offering a competitive privacy–utility trade-off.
Synthetic data is emerging as a strategic solution to persistent barriers in medical artificial intelligence (AI) development, including data scarcity, privacy constraints, and dataset bias. This perspective examines the landscape of synthetic multimodal data in healthcare, including its mechanisms, demonstrated benefi...
S. Reddy, Maryam Haghighat, Andrzej Janusz· Precision and Future Medicin...· 0 citations
We study heterogeneous treatment-effect (HTE) estimation in observational survival studies commonly associated with both censored outcomes and unmeasured confounding. We integrate causal survival forests (CSF) with negative controls (NC) from proximal causal inference and introduce Negative Control Causal Survival Fore...
Zijun Gao, Kyoungeui Hong, Leyi Ma et al.· 0 citations
This methodology extends EVSI when future evidence is expected to be observational and affected by confounding, enabling value-of-information analysis in more realistic and feasible data collection scenarios and provides a principled approach to sample size planning when observational evidence is anticipated.
Although largely preventable, cardiovascular disease (CVD) is the leading cause of death worldwide. Synthetic data generation (SDG) of health data can facilitate data sharing for research and development of personalised cardiovascular disease prevention tools. Current state-of-the-art SDG methods are limited to cross-s...
A. Bertgren, F. Öhberg, P. Soda et al.· bioRxiv· 0 citations
BACKGROUND
Precision dosing integrates patient-specific factors to optimize pharmacotherapy. However, current evidence often relies on limited single-center studies, restricting generalizability.
METHODS
A narrative review of literature on real-world evidence, pharmacogenetics, biomarkers, artificial intelligence (AI...
P. Marquet, M. Labriffe, C. Monchaud et al.· Therapeutic Drug Monitoring· 0 citations
Randomized controlled trials (RCTs) are often considered the gold standard for causal inference, but their implementation can be costly, time-consuming, and sometimes infeasible due to ethical or practical constraints. The so-called target trial emulation framework introduced the systematic use of observational data fo...
Margot Blanchon, Carrie Heller, Maksim Kriukov et al.· Mathematical and Computation...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.